VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution [Yahoo! Finance]
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: Yahoo! Finance
HENDERSON, Nev. Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significant clinical and commercial progress achieved over recent months. Key Highlights: Capture-Seq™ Platform: Paper recently submitted for peer review, underscores a $23 billion [1] annualized opportunity in cancer detection. Lung Cancer: Reimbursement submission in France on track; routine clinical use expected by Q4 2026. Veterinary Breakthrough: 100% specificity achieved in Feline Lymphoma study; $5M milestone payment anticipated. Sepsis & NETosis Validation: Inclusion of the Nu.Q® NETs assay in the $7.3 million government-backed DETECSEPS program in France. Licensing Momentum: Company confirms active discussions with ~10 global diagnostic leaders. Capture-Seq™ Breakthrough in Cancer Detection. We were delighted to submit for peer review a manuscript entitled " Direct analysi
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- VolitionRx Highlights Commercial Momentum and Multi-Pillar ExecutionPR Newswire
- Volition Announces the Appointment of New Distributor for Nu.Q® DiscoverPR Newswire
- VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsPR Newswire
- Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa FoundationPR Newswire
- VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer AssaysPR Newswire
VNRX
Earnings
- 11/13/25 - Miss
VNRX
Sec Filings
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- VNRX's page on the SEC website